Value of 18F-FET PET in Patients With Suspected Tumefactive Demyelinating Disease—Preliminary Experience From a Retrospective Analysis
| Autor: | Helen K Hayward-Könnecke, Massimo Barbagallo, Martin W. Huellner, Abdulrahman A Albatly, Alfred Buck, SJ Schreiner, Spyros Kollias |
|---|---|
| Přispěvatelé: | University of Zurich, Huellner, Martin W |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 610 Medicine & health Standardized uptake value 030218 nuclear medicine & medical imaging Young Adult 03 medical and health sciences 0302 clinical medicine 10043 Clinic for Neuroradiology Biopsy medicine Demyelinating disease 2741 Radiology Nuclear Medicine and Imaging Humans Radiology Nuclear Medicine and imaging Aged Retrospective Studies medicine.diagnostic_test Receiver operating characteristic business.industry Area under the curve Magnetic resonance imaging Retrospective cohort study 10181 Clinic for Nuclear Medicine General Medicine Middle Aged medicine.disease Magnetic Resonance Imaging ROC Curve Positron emission tomography Positron-Emission Tomography Tyrosine Female business Nuclear medicine 030217 neurology & neurosurgery Demyelinating Diseases |
| Zdroj: | Clinical Nuclear Medicine. 43:e385-e391 |
| ISSN: | 1536-0229 0363-9762 |
| Popis: | PURPOSE To investigate the diagnostic value of F-fluoroethyl-L-tyrosine (FET) positron emission tomography (PET) in patients with suspected tumefactive demyelinating disease. METHODS We retrospectively examined FET-PET and MR imaging of 21 patients (12 female, 9 male) with known demyelinating disease and newly diagnosed tumefactive lesions. The maximum standardized uptake value (SUVmax), time activity curves (TAC) and lesion-to-background ratio (TBR) of these lesions were calculated. The standard of reference consisted of biopsy and/or follow-up imaging. FET parameters of true neoplastic lesions and tumefactive demyelinating lesions were compared using Mann-Whitney U-test and receiver operating characteristic (ROC) analysis. RESULTS Nine patients (42.9%) had neoplastic lesions, 12 patients (57.1%) had tumefactive demyelinating lesions. TBRmax, SUVmax and TAC were significantly different between demyelinating lesions and neoplastic lesions: Tumors had a higher TBRmax (3.53 ± 1.09 vs. 1.48 ± 0.31, respectively; P < 0.001) and SUVmax (3.95 ± 1.59 vs. 1.86 ± 0.50, respectively; P < 0.001) than tumefactive demyelinating lesions. The TAC of tumors was significantly higher compared to tumefactive demyelinating lesions at all time points (P < 0.05). ROC analysis revealed that a TBRmax threshold of 2.2 and a SUVmax threshold of 2.5 could reliably differentiate tumor and tumefactive demyelination (area under the curve, 1.000 and 0.958, respectively). CONCLUSION In patients with demyelinating disease, FET-PET parameters TBRmax (cut-off 2.2) and SUVmax (cut-off 2.5) are able to distinguish tumefactive demyelinations from true neoplastic lesions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|